MedTrace Logo

Evaluation of Efficacy of Platelet Rich Plasma as Anew Modality for Treatment of Atrophic Rhinitis

NCT04717960 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-01-22

No results posted yet for this study

Summary

An interventional hospital based study will be undertaken from February 2021 to February 2023 in order to determine the efficacy of platelet rich plasma as a new modality for treatment of patients suffering from atrophic rhinitis in Sohag university hospital.

Conditions

  • Atrophic Rhinitis

Interventions

PROCEDURE

nasal submucosal injection of platelet rich plasma

* The selected region will be infiltrated with a cold saline solution with addition of 1 mL of adrenaline and 25 mL of 2% lignocaine per 500 mL saline. * Platelet-rich plasma is prepared by drawing 10 mL of blood sample from the patient. * The blood will be centrifuged at 1530 g for 10 min to obtain platelet-poor plasma. * This will again centrifuged at 2720 g for 10 min to get platelet-rich plasma. * Approximately 1 mL of platelet-rich plasma will be obtained from 10 mL blood. Usually amount of about 3ml is needed to be injected in each nostril at the affected sites of inferior and middle turbinates, septum and floor of the nose. Platelet rich plasma injected into the affected area after degranulating the platelet by adding 0.5 mL of calcium chloride. * Injection interval of 2 weeks (up to total 3 consecutive injections). * Follow-up duration: 4 months

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Marwa saad, MSc · Sohag University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-10-31
Completion
2023-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04717960 on ClinicalTrials.gov